+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), Disease Type, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 247 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4989597
UP TO OFF until Dec 31st 2022
The Global Childhood Absence Epilepsy Treatment Market size was estimated at USD 206.83 million in 2021, USD 221.63 million in 2022, and is projected to grow at a CAGR 7.33% to reach USD 316.21 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug, the market was studied across Lamotrigine, Phase 2 Drugs, and Valproate.
  • Based on Disease Type, the market was studied across Atypical Absence Seizures and Typical Absence Seizures.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Childhood Absence Epilepsy Treatment market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Childhood Absence Epilepsy Treatment Market, including Abbott Laboratories Inc., AbbVie Inc., Ada Health GmbH, Cavion, Inc., CENTOGENE N.V., Clarivate PLC, Dr. Reddy’s Laboratories Inc., GlaxoSmithKline plc, Insys Therapeutics, Merck & Co., Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Xenon Pharmaceuticals Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Childhood Absence Epilepsy Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Childhood Absence Epilepsy Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Childhood Absence Epilepsy Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Childhood Absence Epilepsy Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Childhood Absence Epilepsy Treatment Market?
6. What is the market share of the leading vendors in the Global Childhood Absence Epilepsy Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Childhood Absence Epilepsy Treatment Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High prevalence of epilepsy in children
5.1.1.2. Rising incidence of typical absence seizures in children
5.1.1.3. Rising funding from contract research organizations (CRO)
5.1.2. Restraints
5.1.2.1. Risk associated with side effects of medications
5.1.3. Opportunities
5.1.3.1. Increased research and development related to new drugs development
5.1.3.2. Approval of funding associated with research and development of new drugs for controlling the symptoms of childhood absence epilepsy
5.1.4. Challenges
5.1.4.1. Lack of efficacious and tolerable initial empirical treatment
5.2. Cumulative Impact of COVID-19
6. Childhood Absence Epilepsy Treatment Market, by Drug
6.1. Introduction
6.2. Lamotrigine
6.3. Phase 2 Drugs
6.4. Valproate
7. Childhood Absence Epilepsy Treatment Market, by Disease Type
7.1. Introduction
7.2. Atypical Absence Seizures
7.3. Typical Absence Seizures
8. Americas Childhood Absence Epilepsy Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Childhood Absence Epilepsy Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Childhood Absence Epilepsy Treatment Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories Inc.
12.2. AbbVie Inc.
12.3. Ada Health GmbH
12.4. Cavion, Inc.
12.5. CENTOGENE N.V.
12.6. Clarivate PLC
12.7. Dr. Reddy’s Laboratories Inc.
12.8. GlaxoSmithKline plc
12.9. Insys Therapeutics
12.10. Merck & Co., Inc.
12.11. Pfizer Inc.
12.12. Sanofi SA
12.13. Teva Pharmaceutical Industries Ltd.
12.14. Xenon Pharmaceuticals Inc.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET DYNAMICS
FIGURE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2021 VS 2027 (%)
FIGURE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2027
FIGURE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 18. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2027
FIGURE 20. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 25. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 26. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2027
FIGURE 28. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 29. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 30. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 32. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 34. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2027
FIGURE 36. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 38. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2027
FIGURE 40. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2027
FIGURE 55. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 67. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 68. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2019-2027 (USD MILLION)
TABLE 17. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 22. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY REGION, 2019-2027 (USD MILLION)
TABLE 23. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY STATE, 2019-2027 (USD MILLION)
TABLE 25. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY REGION, 2019-2027 (USD MILLION)
TABLE 28. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 33. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 35. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 36. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 37. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 38. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 39. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 40. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 41. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 42. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 43. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 44. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 45. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 46. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 47. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 48. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 49. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 50. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 51. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 52. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 53. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 54. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 55. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 56. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 58. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 59. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 61. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 62. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 64. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 65. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 66. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 67. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 68. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 70. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 71. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 72. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 73. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 74. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 75. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 76. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 77. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 79. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 80. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 81. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 82. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 83. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 84. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 85. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 86. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 87. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 88. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 93. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 94. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 95. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 96. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 97. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 98. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 99. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 100. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 101. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 102. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 103. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 104. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 105. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 106. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 107. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 108. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 109. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 110. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 111. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 112. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 113. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 114. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 115. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 116. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 117. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 118. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 119. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 121. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 123. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 124. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 125. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 126. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 127. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 128. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 129. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RANKING
TABLE 130. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
TABLE 131. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET MERGER & ACQUISITION
TABLE 132. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 133. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 134. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET INVESTMENT & FUNDING
TABLE 135. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 136. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • Ada Health GmbH
  • Cavion, Inc.
  • CENTOGENE N.V.
  • Clarivate PLC
  • Dr. Reddy’s Laboratories Inc.
  • GlaxoSmithKline plc
  • Insys Therapeutics
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Xenon Pharmaceuticals Inc.

Methodology

Loading
LOADING...